EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Global real‐world data on hemodiafiltration: An opportunity to complement clinical trial evidence

Linda H Ficociello iD, Ellen Busink, Dixie-Ann Sawin, Anke Winter

Seminars in Dialysis · 2022-09 · 35 (5) · 440-445

DOI: 10.1111/sdi.13085 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Seminars in Dialysis, online erschienen am 19.04.2022. Verfasst von Linda H Ficociello und 3 weiteren Autor:innen. Beteiligte Einrichtung: Global Medical Office, Fresenius Medical Care, Waltham, MA, USA. Hauptthemen laut MEDLINE: Hemodiafiltration, Kidney Failure, Chronic. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fresenius Medical Care North America.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hemodiafiltration (HDF) is a renal replacement therapy that utilizes both diffusive clearance and convective transport to achieve greater clearance of middle‐molecular‐weight solutes. Among other factors, important prerequisites for the implementation of HDF include access to high‐flux dialyzers, achievement of high blood flow rates, and availability of high volumes of sterile substitution/replacement fluids. Online hemodiafiltration (OL‐HDF) is an established kidney replacement therapy, frequently used in many countries. Although in the United States, some prerequisites (e.g., access to high‐flux dialyzers and achievement of high blood flow rates) for OL‐HDF treatment are readily available; however, a machine capable of generating the online solution for OL‐HDF is currently not available. As the clinical experience with HDF accumulates globally, it is worth examining the evidence for this kidney replacement therapy as used in routine clinical care. Such real‐world evidence is increasingly recognized as valuable by clinicians and may inform regulatory decisions. In this review, we will focus on emerging global real‐world data derived from routine clinical practices and examine how these data may complement those derived from clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HemodiafiltrationKidney Failure, ChronicHumansRenal Dialysis

Autor:innen und Institutionen

  • Global Medical Office, Fresenius Medical Care, Waltham, MA, USA.
  • Health Economics, Market Access and Political Affairs EMEA, Fresenius Medical Care Deutschland GmbH, Bad Homburg, Germany.
  • Global Medical Office, Fresenius Medical Care, Bad Homburg, Germany.

ORCID-Profile: Linda H Ficociello

Förderung

  • Fresenius Medical Care North America

Zitieren

APA

Ficociello, L. H., Busink, E., Sawin, D. A., & Winter, A. (2022). Global real‐world data on hemodiafiltration: An opportunity to complement clinical trial evidence. Seminars in Dialysis, 35(5), 440-445. https://doi.org/10.1111/sdi.13085

Vancouver

Ficociello LH, Busink E, Sawin DA, Winter A. Global real‐world data on hemodiafiltration: An opportunity to complement clinical trial evidence. Seminars in Dialysis. 2022;35(5):440-445. doi:10.1111/sdi.13085

BibTeX
@article{Ficociello2022,
  author = {Ficociello, Linda H and Busink, Ellen and Sawin, Dixie-Ann and Winter, Anke},
  title = {Global real‐world data on hemodiafiltration: An opportunity to complement clinical trial evidence},
  journal = {Seminars in Dialysis},
  year = {2022},
  volume = {35},
  number = {5},
  pages = {440--445},
  doi = {10.1111/sdi.13085}
}
Kostenlos starten →